eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis
American Journal of Respiratory Cell and Molecular Biology · 2025
DOI: 10.1165/rcmb.2024-0342oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2025. Verfasst von Nancy G Casanova und 33 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammation Science and Systems Medicine and. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Nicotinamide Phosphoribosyltransferase. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disorder without curative therapies, underscoring the critical unmet need for identification of novel therapeutic strategies. eNAMPT (extracellular nicotinamide phosphoribosyltransferase) is a damage-associated molecular pattern protein (DAMP) and TLR4 (Toll-like receptor 4) ligand that contributes to the severity of radiation-induced lung fibrosis and nonalcoholic steatohepatitis–associated hepatic fibrosis. This study investigates eNAMPT as a druggable target in human and preclinical IPF using the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb). Blood, peripheral blood mononuclear cells (PBMCs), and lung tissues from patients with IPF and from an experimental bleomycin-induced lung fibrosis model in C57Bl6 mice were analyzed. Biochemical and histologic measurements, as well as gene expression through bulk and single-cell RNA sequencing of human PBMCs and murine lung tissues, were performed. Human studies revealed NAMPT expression to be significantly increased in plasma, lung tissues, and PBMCs from subjects with IPF, correlating with disease severity and inversely associated with IPF survival. Bleomycin-exposed mice exhibited increased inflammatory indices associated with lung fibrosis development (including NAMPT levels), as well as physiologic lung stiffening and TGF-β pathway–related protein and gene expression, with each index significantly mitigated in mice receiving ALT-100 mAb. Single-cell RNA sequencing studies demonstrated the ALT-100 mAb to reverse the bleomycin-induced dramatic expansion of alveolar type 2 epithelium and induction of endothelial cell– and epithelial cell–to–mesenchymal/myofibroblast transitions. These finding support the fundamental involvement of eNAMPT/TLR4 signaling pathway in lung fibrosis pathobiology, with eNAMPT neutralization a viable therapeutic strategy to directly address the unmet need for novel IPF treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Inflammation Science and Systems Medicine and.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of South Florida School of Medicine, Tampa, Florida.
- Departments of Pathology, Pediatrics, Medicine, and Cellular and Molecular Medicine and.
- Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
- Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Baylor University, Houston, Texas.
- Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama.
ORCID-Profile: Nancy G Casanova, Avraham Unterman, Panayiotis V Benos, Naftali Kaminski
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIEHS NIH HHS
- Congressionally Directed Medical Research Programs
- NINDS NIH HHS
- National Heart, Lung, and Blood Institute
- Division of Intramural Research
Zitieren
APA
Casanova, N. G., Herazo-Maya, J. D., Kempf, C. L., Sun, B. L., Song, J. H., Hernandez, A., Canizales Galaviz, J., Sun, X., Camp, S. M., Ledford, J. G., Hellinger, R. D., Rodriguez, M., Zhao, A. Y., Unterman, A., Rosas, I., Duncan, S., Thannikal, V. J., Hufford, M. K., Ahmed, M., …, & Garcia, J. G. N. (2025). eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2024-0342oc
Vancouver
Casanova NG, Herazo-Maya JD, Kempf CL, Sun BL, Song JH, Hernandez A, et al. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 2025. doi:10.1165/rcmb.2024-0342oc
BibTeX
@article{Casanova2025,
author = {Casanova, Nancy G and Herazo-Maya, Jose D and Kempf, Carrie L and Sun, Belinda L and Song, Jin H and Hernandez, Annie and Canizales Galaviz, Jason and Sun, Xiaoguang and Camp, Sara M and Ledford, Julie G and Hellinger, Riley D and Rodriguez, Marisela and Zhao, Amy Y and Unterman, Avraham and Rosas, Ivan and Duncan, Steve and Thannikal, Victor J and Hufford, Matthew K and Ahmed, Mohamed and Zaghloul, Nahla and Gupta, Akash and Bime, Christian and Sammani, Saad and Stansfield, Ben N and Chen, Jinjing and Anandhan, Annadurai and Disney, Matthew D and Ooi, Aikseng and Kee, Shaira L and Karampitsakos, Theodoros and Benos, Panayiotis V and Kaminski, Naftali and Zhang, Donna and Garcia, Joe G N},
title = {eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2025},
doi = {10.1165/rcmb.2024-0342oc}
}
EUVIMED